Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma

Simple Summary Kallikrein-related peptidases have tumour-biological roles and are dysregulated in many cancers. Only a few studies have reported their upregulation in pancreatic cancer and linked them to poor prognosis. By interrogating publicly available and our own datasets, we studied their expression in patient-derived tissues and pancreatic cancer cells. We found several kallikrein-related peptidases that were upregulated, in particular kallikrein-related peptidase 6 at the forefront of the tumour area. We then tested the effect of a kallikrein-related peptidase 6 inhibitor on cancer cell functions. Because the majority of patients present with inoperable disease, a targeted therapeutic intervention may have a positive impact on the survival of this patient population. Abstract As cancer-associated factors, kallikrein-related peptidases (KLKs) are components of the tumour microenvironment, which represents a rich substrate repertoire, and considered attractive targets for the development of novel treatments. Standard-of-care therapy of pancreatic cancer shows unsatisfactory results, indicating the need for alternative therapeutic approaches. We aimed to investigate the expression of KLKs in pancreatic cancer and to inhibit the function of KLK6 in pancreatic cancer cells. KLK6, KLK7, KLK8, KLK10 and KLK11 were coexpressed and upregulated in tissues from pancreatic cancer patients compared to normal pancreas. Their high expression levels correlated with each other and were linked to shorter survival compared to low KLK levels. We then validated KLK6 mRNA and protein expression in patient-derived tissues and pancreatic cancer cells. Coexpression of KLK6 with KRT19, αSMA or CD68 was independent of tumour stage, while KLK6 was coexpressed with KRT19 and CD68 in the invasive tumour area. High KLK6 levels in tumour and CD68+ cells were linked to shorter survival. KLK6 inhibition reduced KLK6 mRNA expression, cell metabolic activity and KLK6 secretion and increased the secretion of other serine and aspartic lysosomal proteases. The association of high KLK levels and poor prognosis suggests that inhibiting KLKs may be a therapeutic strategy for precision medicine.

[1]  Yisroel Brumer,et al.  Application of machine learning to large in vitro databases to identify drug–cancer cell interactions: azithromycin and KLK6 mutation status , 2021, Oncogene.

[2]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[3]  E. Jaffee,et al.  The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities , 2020, Nature Reviews Clinical Oncology.

[4]  D. Loessner,et al.  3D approaches to model the tumor microenvironment of pancreatic cancer , 2020, Theranostics.

[5]  R. Midura,et al.  KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease. , 2020, The Journal of clinical investigation.

[6]  M. Hidalgo,et al.  From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer , 2019, Nature Reviews Clinical Oncology.

[7]  J. Clements,et al.  A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. , 2019, Biomaterials.

[8]  S. Love,et al.  Exploring the putative role of kallikrein‐6, calpain‐1 and cathepsin‐D in the proteolytic degradation of α‐synuclein in multiple system atrophy , 2018, Neuropathology and applied neurobiology.

[9]  M. Hollenberg,et al.  Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation , 2018, Biological chemistry.

[10]  I. Scarisbrick,et al.  Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms , 2018, Biological chemistry.

[11]  Aubry K. Miller,et al.  A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering , 2018, The Journal of Biological Chemistry.

[12]  Zhi-gang Zhang,et al.  Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC. , 2018, Biochemical and biophysical research communications.

[13]  Seiji Nakamura,et al.  Differential roles of kallikrein-related peptidase 6 in malignant transformation and ΔNp63β-mediated epithelial-mesenchymal transition of oral squamous cell carcinoma. , 2017, Oral oncology.

[14]  X. Tan,et al.  3D collagen fibrillar microstructure guides pancreatic cancer cell phenotype and serves as a critical design parameter for phenotypic models of EMT , 2017, PloS one.

[15]  R. Eils,et al.  Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response , 2017, Clinical Cancer Research.

[16]  M. Reni,et al.  Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. , 2017, Cancer treatment reviews.

[17]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[18]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[19]  G. Sotiropoulou,et al.  KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species , 2016, Oncotarget.

[20]  I. Scarisbrick,et al.  Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis , 2016, Biological chemistry.

[21]  J. Clements,et al.  The kallikrein-related peptidase family: Dysregulation and functions during cancer progression. , 2016, Biochimie.

[22]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[23]  N. Grabe,et al.  Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients , 2015, Molecular Cancer.

[24]  G. Poda,et al.  Unleashing the therapeutic potential of human kallikrein-related serine proteases , 2015, Nature Reviews Drug Discovery.

[25]  A. Scorilas,et al.  Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma , 2014, Biological chemistry.

[26]  O. Musso,et al.  Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor , 2014, Biological chemistry.

[27]  J. Uhm,et al.  Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. , 2013, Neuro-oncology.

[28]  J. Clements,et al.  Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. , 2012, Gynecologic oncology.

[29]  M. Tsao,et al.  Expression of Kallikrein-Related Peptidase 7 Predicts Poor Prognosis in Patients with Unresectable Pancreatic Ductal Adenocarcinoma , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[30]  R. Langer,et al.  Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients , 2012, Biological chemistry.

[31]  Hannah J. Whiteman,et al.  AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. , 2011, Cancer research.

[32]  M. Blaber,et al.  Expression and function of the Kallikrein-related peptidase 6 in the human melanoma microenvironment , 2011, The Journal of investigative dermatology.

[33]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[34]  M. Schmitt,et al.  Interdependence of kallikrein-related peptidases in proteolytic networks , 2010, Biological chemistry.

[35]  E. Diamandis,et al.  Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines , 2008, Biological chemistry.

[36]  M. Blaber,et al.  Activation profiles of human kallikrein‐related peptidases by proteases of the thrombostasis axis , 2008, Protein science : a publication of the Protein Society.

[37]  R. Haun,et al.  Expression of Kallikrein 7 Diminishes Pancreatic Cancer Cell Adhesion to Vitronectin and Enhances Urokinase-Type Plasminogen Activator Receptor Shedding , 2008, Pancreas.

[38]  C. Pilarsky,et al.  Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma , 2008, British Journal of Cancer.

[39]  Jihun Lee,et al.  Activation Profiles and Regulatory Cascades of the Human Kallikrein-related Peptidases* , 2007, Journal of Biological Chemistry.

[40]  C. Flechtenmacher,et al.  Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. , 2007, Cancer research.

[41]  Sarah K. Johnson,et al.  Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E‐cadherin , 2007, Cancer.

[42]  E. Diamandis,et al.  Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour Cells , 2004, Tumor Biology.

[43]  Moses Rodriguez,et al.  Targeting kallikrein 6‐proteolysis attenuates CNS inflammatory disease , 2004, The FASEB Journal.

[44]  G. Yousef,et al.  In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. , 2004, Anticancer research.

[45]  Christine A Iacobuzio-Donahue,et al.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.